ARA-290 (Cibinetide)
Cibinetide · pHBSP
A non-erythropoietic EPO-derived peptide studied in humans for neuropathic pain and inflammation.
Class
Innate repair receptor agonist
Half-life
Short (minutes)
Evidence
Limited human data
Limited human data
Small open-label studies, case series, or trials in a narrow population. Directionally informative, not conclusive.
Overview
ARA-290 is an 11-amino-acid peptide derived from a region of erythropoietin (EPO), engineered to keep EPO's tissue-protective, anti-inflammatory activity while removing the effect on red-blood-cell production that makes EPO risky. It acts on the 'innate repair receptor'.
It has been through human trials, most notably for the small-fiber neuropathy of sarcoidosis and for diabetic neuropathic pain, where it improved pain scores and measures of nerve fiber density. The evidence is early but genuinely human, and its safety profile in trials has been clean because it lacks EPO's clotting/hematologic effects.
How it works
- Agonises the innate repair receptor (a heteromer of EPO receptor and beta-common receptor).
- Anti-inflammatory and tissue-protective signalling without stimulating erythropoiesis.
- Promotes small-fiber nerve repair in studied neuropathies.
What the research shows
Researched effects
- Reduced neuropathic pain in sarcoidosis small-fiber neuropathy (human trials)
- Improved corneal nerve fiber measures and pain in diabetic neuropathy studies
- Anti-inflammatory effects without raising hematocrit
Limitations & what it won't do
- Human trials are small and early-phase.
- Very short half-life; typically dosed daily.
- Not FDA approved.
Dosing protocols
These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.
Trial-referenced protocol
2–4 mgTrials used ~4 mg subcutaneous daily. Documented for reference.
Reconstitution & measuring your dose
Handling
- Typical vial sizes
- 10 · 50 mg
- Suggested BAC water
- 2 mL
- Storage
- Lyophilised powder refrigerated at 2–8 °C, protected from light.
- After reconstitution
- Reconstituted: approximately 30 days refrigerated.
Why 2 mL? A 10 mg vial in 2 mL yields 5 mg/mL — a 4 mg dose lands on 80 units of a U-100 syringe.
Dose calculator
Draw to
8units
= 0.08 mL · 250 mcg per unit
Concentration
25000 mcg/mL
Doses per vial
25
Side effects
Common
- Injection-site reactions
- Generally well tolerated in trials
Serious / rare
- Poorly characterised outside trials, though it lacks EPO's clotting risk
Contraindications & interactions
Do not use if you have
- Pregnant, breastfeeding, or trying to conceive
No pregnancy safety data.
Use caution if you have
- Autoimmune condition
Immune-modulating; discuss with a specialist in autoimmune disease.
What to monitor
- Neuropathic symptoms
- Inflammatory markers if relevant
Commonly combined with
ARA-290 (Cibinetide): common questions
Is ARA-290 (Cibinetide) approved for human use?
Most research peptides, including ARA-290 (Cibinetide), are not FDA-approved for general human use and are sold as research chemicals "not for human consumption." Check the legal-status and evidence badges above, and consult a licensed physician — this page is educational only.
How strong is the evidence for ARA-290 (Cibinetide)?
On this site ARA-290 (Cibinetide) is graded "Limited human data". Small open-label studies, case series, or trials in a narrow population. Directionally informative, not conclusive. We grade every claim so you can weigh it honestly rather than by hype.
How is ARA-290 (Cibinetide) reconstituted and dosed?
See the protocols and reconstitution details above for reference ranges, then use the dose calculator to convert a vial's mg, your bacteriostatic-water volume, and target dose into exact insulin-syringe units. Dosing shown is a reference, not a recommendation.
What should I screen for before considering ARA-290 (Cibinetide)?
Run your goals, medical history, and current medications through the assessment — it flags contraindications and interactions and will hard-stop unsafe matches — and confirm everything with a licensed physician. Any use is at your own risk.
References
Research & educational information only — not medical advice.
You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.
Want to know if ARA-290 (Cibinetide) fits your goals and history?
The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.
Start the assessment